Assessment in Leeds of Biomarkers Early after Renal Transplantation

• Research type

  Research Study

• Full title

  Assessment in Leeds of Biomarkers Early after Renal Transplantation (ALBERT) study

• IRAS ID

  154894

• Contact name

  Richard J Baker

• Contact email

  richard-j.baker@nhs.net

• Sponsor organisation

  Leeds NHS Teaching Hospital NHS Trust

• Duration of Study in the UK

  2 years, 11 months, 28 days

• Research summary

  While the rates of renal transplant graft survival at one year are extremely good there is still a major problem with the graft loss over the longer term. All patients with kidney transplants require immunosuppressive drugs for the lifetime of their transplant to prevent the rejection process. Unfortunately these drugs are toxic and can cause significant side effects. There is an urgent need for simple tests which could guide therapy and individualise treatment. For any given patient it might then become possible to decide whether they require more, less or the same amount of immunosuppression.

  In Leeds we wish to study three types of patients:

  • Those who are waiting in the transplant list
  • Recipients of a recent kidney transplant
  • Individuals who need a biopsy of their kidney for the usual clinical reasons

  In these individuals we wish to carry out a number of minimally invasive tests to see whether they can predict longer term clinical outcomes. These tests will be carried out on small volumes of blood and urine and have been selected based on both our own group’s work and that of others. All patients under the care of the renal transplant unit in Leeds will be eligible for recruitment and the work will be carried out in Leeds. The study will be completed within 5 years from the beginning of recruitment.

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  16/YH/0025

• Date of REC Opinion

  29 Feb 2016

• REC opinion

  Further Information Favourable Opinion